Shares of Aerie Pharmaceuticals surged 16.3% on Feb.
After market close yesterday, Aerie Pharmaceuticals Inc (NASDAQ:AERI) announced positive 3-month top-line efficacy results from its pivotal phase III Mercury 2 trial for glaucoma eye …
Interpace Diagnostics Group Inc (NASDAQ:IDXG) shares rose nearly 8% in after-hours trading Wednesday, after the company announced that it is launching a new biomarker …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) announced that it has entered into a lease agreement with the Industrial Development Agency (IDA) of Ireland for a …
Needham’s Serge Belanger has reiterated his Buy rating on Aerie Pharma (NASDAQ: AERI) despite a stalled manufacturing pre-inspection that has caused the firm to delay …
Dewey Steadman at research firm Canaccord has come out with a bullish call on shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI). The analyst assumed …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) reported that it has been notified by its third party manufacturing vendor that the manufacturing line related to Rhopressa in …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) announced the appointment of Judith J. Robertson as Chief Commercial Officer, reporting to Thomas Mitro, Aerie President and Chief …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) announced the completion of patient enrollment in the Company’s second Phase 3 registration trial (“Mercury 2”) of Roclatan (netarsudil/latanoprost …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) reported the successful 90-day topline efficacy results of its Rocket 4 Phase 3 clinical trial of product candidate RhopressaTM, a …
